Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.
Milestone Pharmaceuticals Inc. develops and commercializes cardiovascular medicines, centered on CARDAMYST (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also being developed for symptomatic episodic attacks associated with AFib-RVR.
Company news commonly covers CARDAMYST commercialization, payer formulary access, real-world evidence work such as the RESET-PSVT registry, cardiovascular conference presentations, regulatory updates, financial results and business updates. Milestone also reports equity inducement grants and other corporate actions tied to its Nasdaq-listed common shares.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.